Marquette Asset Management LLC raised its holdings in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Rating) by 56.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,090 shares of the company’s stock after acquiring an additional 23,237 shares during the period. Marquette Asset Management LLC owned about 0.27% of Spruce Biosciences worth $112,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. lifted its stake in Spruce Biosciences by 26.0% in the first quarter. BlackRock Inc. now owns 529,554 shares of the company’s stock worth $1,064,000 after acquiring an additional 109,226 shares during the period. State Street Corp lifted its position in Spruce Biosciences by 61.8% during the first quarter. State Street Corp now owns 205,459 shares of the company’s stock valued at $413,000 after buying an additional 78,490 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Spruce Biosciences by 317.7% during the first quarter. Bank of New York Mellon Corp now owns 116,501 shares of the company’s stock valued at $234,000 after acquiring an additional 88,608 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Spruce Biosciences by 180.7% during the first quarter. Renaissance Technologies LLC now owns 111,700 shares of the company’s stock valued at $225,000 after acquiring an additional 71,900 shares in the last quarter. 77.24% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Spruce Biosciences in a report on Tuesday, June 21st. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $9.43.
Spruce Biosciences Price Performance
Spruce Biosciences (NASDAQ:SPRB – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01. Equities research analysts anticipate that Spruce Biosciences, Inc. will post -2.14 earnings per share for the current fiscal year.
Spruce Biosciences Company Profile
Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial.
- Get a free copy of the StockNews.com research report on Spruce Biosciences (SPRB)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.